Brain tumor patients get immunotherapy before surgery in bold new trial
NCT ID NCT05423210
First seen Jan 05, 2026 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This early-phase pilot study is testing whether combining the immunotherapy drug atezolizumab with targeted radiation before surgery can help treat newly diagnosed glioblastoma, an aggressive brain cancer. Twelve patients will receive two weeks of radiation plus two doses of atezolizumab, then undergo standard surgery, followed by more atezolizumab. The goal is to see if this approach is safe and may slow tumor progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stony Brook University Hospital
RECRUITINGStony Brook, New York, 11794, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (Tecentriq) plus fractionated stereotactic radiotherapy
What this could lead to
If this works, it could point toward a new treatment approach that combines immunotherapy with radiation to improve outcomes for glioblastoma patients.
What could go wrong
This is a very early, small pilot study with only 12 participants. It is designed mainly to test safety and feasibility, not to prove effectiveness. Glioblastoma is a very aggressive cancer, and many promising treatments have failed before.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.